anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Articles of clothing, such as stocking, socks, knee-leggings, mittens, gloves, underwear, caps, or materials employed in making such articles, or surgical dressings, such as lining material or cottonwool, are rendered radio-active for therapeutic purposes by impregnating them, as by spraying, with a solution of radium chloride, and subsequently treating the impregnated material with an insolubilizing agent such as Glauber's salt solution.  The products may be treated with protective agents such as wax, or oil emulsions. The Specification as open to inspection under Sect. 91 describes also the application of the radio-active material in finely divided form and the use of a solution of any radio-active salt subsequently insolubilized.  This subject-matter does not appear in the Specification as accepted.ALSO:Articles of clothing, such as stockings, socks, knee-leggings, mittens, gloves, underwear, caps, or materials employed in making such articles, or surgical dressings, such as lining material or cottonwool, are rendered radioactive for therapeutic purposes by impregnating them, as by spraying, with a solution of radium chloride, and subsequently treating the impregnated material with an insolubilizing agent such as Glauber's salt solution.  The products may be treated with protective agents such as wax, or oil emulsions.  The Specification as open to inspection under Sect. 91 also describes the application of the radioactive material in finely divided form and the use of a solution of any radioactive salt subsequently insolubilized.  This subject-matter does not appear in the Specification as accepted.ALSO:Articles of clothing, such as stockings, socks, knee-leggings, mittens, gloves, underwear, caps, or materials employed in making such articles, or surgical dressings, such as lining material or cottonwool, are rendered radio-active for therapeutic purposes by impregnating them, as by spraying, with a solution of radium chloride, and subsequently treating the impregnated material with an insolubilizing agent such as Glauber's salt solution.  The products may be treated with protective agents such as wax, or oil emulsions.  The Specification as open to inspection under Sect. 91 also describes the application of the radio-active material in finely-divided form and the use of a solution of any radio-active salt subsequently insolubilized.  This subject-matter does not appear in the Specification as accepted.
Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement.
This study aims to develop a prognostic signature based on m6A-related lncRNAs for clear cell renal cell carcinoma (ccRCC). Differential expression analysis and Pearson correlation analysis were used to identify m6A-related lncRNAs associated with patient outcomes in The Cancer Genome Atlas (TCGA) database. Our approach led to the development of an m6A-related lncRNA risk score (MRLrisk), formulated using six identified lncRNAs: NFE4, AL008729.2, AL139123.1, LINC02154, AC124854.1 and ARHGAP31-AS1. Higher MRLrisk was identified as a risk factor for patients' prognosis in ccRCC. Furthermore, an MRLrisk-based nomogram was developed and demonstrated as a reliable tool for prognosis prediction in ccRCC. Enrichment analysis and tumor mutation signature studies were conducted to investigate MRLrisk-related biological phenotypes. The tumor immune dysfunction and exclusion (TIDE) score was employed to infer patients' response to immunotherapy, indicating a negative correlation between high MRLrisk and immunotherapy response. Our focus then shifted to LINC02154 for deeper exploration. We assessed LINC02154 expression in 28 ccRCC/normal tissue pairs and 3 ccRCC cell lines through quantitative real-time polymerase chain reaction (qRT-PCR). Functional experiments, including EdU incorporation, flow cytometry and transwell assays, were performed to assess the role of LINC02154 in ccRCC cell functions, discovering that its downregulation hinders cancer cell proliferation and migration. Furthermore, the influence of LINC02154 on ccRCC cells' sensitivity to Sunitinib was explored using CCK-8 assays, demonstrating that decreased LINC02154 expression increases Sunitinib sensitivity. In summary, this study successfully developed an MRLrisk model with significant prognostic value for ccRCC and established LINC02154 as a critical biomarker and prospective therapeutic target in ccRCC management.
After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU).
GSK249320 is a humanised monoclonal antibody (mAb) that binds with high specificity to myelin-associated glycoprotein (MAG) and antagonises or neutralises MAG-mediated inhibition and has been shown to improve functional recovery after stroke in pre-clinical models, possibly by promoting neuroregeneration and plasticity. The present study is the first in patients with stroke. The main aim of this study is to select tolerated doses of GSK249320 that can be used in future trials to evaluate its efficacy in improving clinical function in patients recovering from stroke. This clinical trial is designed as a placebo-controlled, single-blind, multicenter study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of escalating repeat IV doses of GSK249320. Three sequential dose escalation cohorts (1, 5 and 15 mg/kg) are planned, with 8 patients on placebo and 8 on active in cohort 1 and 4 patients on placebo and 8 on active in cohorts 2 and 3. Each patient will receive 2 repeat IV doses 9 ± 1 days apart and assessments will extend to at least 16 weeks.
PURPOSE: Provided is a method of preparing a proteoglycan having a high anticancer activity by fermenting fruit bodies of a mushroom using mycelia of basidiomycetes and extracting the proteoglycan therefrom. The proteoglycan is capable of being used as a therapeutic anticancer agent. CONSTITUTION: Minerals and organic nutrients are added to fruit bodies of a mushroom to produce a fermentation mixture. Thereafter, mycelia of basidiomycetes or yeast are inoculated into the fermentation mixture, followed by cultivation at 20 to 37deg.C for 1 to 15 days, and extraction of proteoglycan therefrom. The mushroom includes Coriolus versicolor, Phellinus linteus, Inonotus obliquus, Ganoderma lucidum, Grifola frondosa, Panus rudis Fr. and Lentinus edodes. The fermentation mixture contains 1 to 5% by weight of a yeast extract, 3 to 30% by weight of sawdust, rice bran, peptone, glucose, together with fruit body powder of the mushroom.
BACKGROUND: Epigenome-wide association studies (EWAS) have identified CpG sites associated with HIV infection in blood cells in bulk, which offer limited knowledge of cell-type specific methylation patterns associated with HIV infection. In this study, we aim to identify differentially methylated CpG sites for HIV infection in immune cell types: CD4+ T-cells, CD8+ T-cells, B cells, Natural Killer (NK) cells, and monocytes.
METHODS: Applying a computational deconvolution method, we performed a cell-type based EWAS for HIV infection in three independent cohorts (Ntotal = 1,382). DNA methylation in blood or in peripheral blood mononuclear cells (PBMCs) was profiled by an array-based method and then deconvoluted by Tensor Composition Analysis (TCA). The TCA-computed CpG methylation in each cell type was first benchmarked by bisulfite DNA methylation capture sequencing in a subset of the samples. Cell-type EWAS of HIV infection was performed in each cohort separately and a meta-EWAS was conducted followed by gene set enrichment analysis.
RESULTS: The meta-analysis unveiled a total of 2,021 cell-type unique significant CpG sites for five inferred cell types. Among these inferred cell-type unique CpG sites, the concordance rate in the three cohorts ranged from 96% to 100% in each cell type. Cell-type level meta-EWAS unveiled distinct patterns of HIV-associated differential CpG methylation, where 74% of CpG sites were unique to individual cell types (false discovery rate, FDR <0.05). CD4+ T-cells had the largest number of unique HIV-associated CpG sites (N = 1,624) compared to any other cell type. Genes harboring significant CpG sites are involved in immunity and HIV pathogenesis (e.g. CD4+ T-cells: NLRC5, CX3CR1, B cells: IFI44L, NK cells: IL12R, monocytes: IRF7), and in oncogenesis (e.g. CD4+ T-cells: BCL family, PRDM16, monocytes: PRDM16, PDCD1LG2). HIV-associated CpG sites were enriched among genes involved in HIV pathogenesis and oncogenesis that were enriched among interferon-α and -γ, TNF-α, inflammatory response, and apoptotic pathways.
CONCLUSION: Our findings uncovered computationally inferred cell-type specific modifications in the host epigenome for people with HIV that contribute to the growing body of evidence regarding HIV pathogenesis.
There are two aspects to this study: First, the investigators will compare two training and supervision processes. One group, comprised of facilitators from rural settings, will be trained and supervised by two master trainers from the University of Pittsburgh Medical Center (UPMC) Center for Autism and Developmental Disorders (CADD). A second group, comprised of facilitators from an agency serving primarily low-income households and located near Pittsburgh, PA, will be trained and supervised in a face-to-face manner. Both groups will receive 15 hours of training spread over the course of 2-3 months (in summer 2023). The focus of these sessions will be to introduce and train staff on the CST model, ensure their understanding of the curriculum, and to help them gain proficiency in administration. During the training phase, both groups will practice administration of activities and will be provided feedback. The master trainers will also assist the newly trained facilitators in navigating recruitment and organization of their first CST groups. Upon initiation of the CST groups, facilitators will receive 1 hour of supervision per week, either in person or via TEAMS. Supervision will extend over the 9 group sessions and 3 home visits per family (fall 2023). These supervision sessions will allow the facilitators to ask questions, obtain feedback, and troubleshoot any challenges. The investigators will also collect pre and post measures (baseline and week 12) from the parents participating in the CST groups to determine if the type of training provided to the facilitators (face-to-face versus remote) impacted parent progress. We have also added an additional research question in which we compare face-to-face CST sessions with remote CST sessions.
ARNUITY ELLIPTA will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since ARNUITY ELLIPTA is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of ARNUITY ELLIPTA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose.

Because of the possibility of significant systemic absorption of ICS in sensitive patients, patients treated with ARNUITY ELLIPTA should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when fluticasone furoate is administered at higher than recommended doses over prolonged periods of time. If such effects occur, reduce the dose of ARNUITY ELLIPTA slowly, consistent with accepted procedures for reducing systemic corticosteroids, and consider other treatments for management of asthma symptoms.
PURPOSE: To obtain a lymphotropic preparation of malotilate, containing malotilate dissolved in an oil and fat, capable of keeping the malotilate in the lymphatic system at a high concentration and effective e.g. for suppressing the metastasis of cancer. CONSTITUTION: This agent is prepared by dissolving diisopropyl-1,3-dithiol-2- ylidene malonate (malotilate) in an oil and fat such as soybean oil or olive oil and optionally compounding a surfactant, an antiseptic agent, a stabilizer, etc., to the solution. The amount of the other additives is 1-5,000 pts.wt. based on 1 pt.wt. of malotilate and the mixture is formed in the form of an emulsion. Since the malotilate is used in the form dissolved in an oil and fat, the lymphotropic property of malotilate is remarkably increased, the metabolic reaction in the liver is avoided and the major part of malotilate is present in the lymph in an unreacted state.
The invention discloses a preparation method of a biosynthetic silver nanoparticle. The invention also discloses a preparation method of the biosynthesis silver nanoparticle carrying the microRNA. The invention also discloses application of the biosynthesis silver nanoparticle carrying the microRNA in preparation of a nano-drug delivery system for targeted induction of drug-resistant liver cancer cell apoptosis. The invention also discloses a nano-drug delivery system for targeted induction of drug-resistant liver cancer cell apoptosis. The drug delivery system of the invention synthesizes the nanometer material through organism tissues, thereby improving the biocompatibility of the material; the non-chemotherapeutic drug loaded microRNA reduces toxic and side effects and avoids multi-drug resistance, thereby improving the treatment effect on drug-resistant liver cancer. In addition, the drug delivery system also has the advantages of targeting, controlled release and visualization, and can realize the diagnosis and treatment integration of the drug-resistant liver cancer.
This study will have a within-subject design. Participants will complete a baseline session (S1) and three intervention sessions. Specifically, participants will complete one intervention session consisting of episodic future thinking (EFT) and low-intensity focused ultrasound (LIFU), a second intervention session consisting of EFT and a control condition for LIFU ("sham-LIFU"), and an intervention session consisting of a control condition for EFT, called control episodic thinking (CET) and LIFU. Measures of chronic pain, alcohol valuation, alcohol craving, and delay discounting will be collected before and after each intervention session. The EFT intervention has participants generate positive events and related cues through a researcher-administered interview-based questionnaire. Participants will be asked to think about and describe positive events that could occur at each of the 6 delays in the future (i.e., 1 week, 1 month, 3 months, 1 year, 5 years, and 25 years). During the LIFU condition, participants will have an ultrasound transducer placed on their head, where brief ultrasound pulses are delivered to the desired brain area. CET requires participants to think about and describe positive events that occurred at each of 6 delays in the past (e.g., last night, yesterday in the afternoon, yesterday in the evening, yesterday in the morning, yesterday in the night, and the night before). After generating these cues participants will be asked to read and consider their cues as they complete the measures again that were collected prior to the cue generation. The sham LIFU condition may be active with ultrasound blocking, or inactive so that it would not deliver stimulation. All participants will complete all three intervention sessions. The first day will be the consent, MRI, and CT scans required for the LIFU intervention. The remaining three intervention sessions will occur in a counterbalanced order. The first and second sessions will be separated by 2-3 weeks, and the remaining sessions will be separated by approximately 1 week.
FIELD: medicinal industry, pharmacy. SUBSTANCE: invention relates to making nitroglycerin sublingual tablets used for arresting stenocardia acute attacks. The novel antianginal drug has the following components, wt.-%: nitroglycerin, 0.6-0.89; glucose, 5.24-70.72; lactose, 23.07-85.42; starch, 5.0-8.13; stearic acid and/or calcium or magnesium stearate, 0.2-1.0. For making the novel antianginal agent glucose is wetted with nitroglycerin solution in polar organic solvent at the ratio of components as measured to obtain nitroglycerin concentration in dry mixture with glucose 1-12 wt.-%. Obtained mass is dried and mixed with lactose. Then the mixture is wetted with 3-10% starch paste solution, dried and subjected for dry granulation. Mass for tabletting is powdered with the mixture of starch and stearic acid or calcium or magnesium stearate. Tabletting is carried out in rotor tablet-press unit. Method provides making nitroglycerin tablets in industrial equipment, tablet decomposition time is less 60 s and tablets are stable for one year. Tablet quality corresponds to pharmacopoeia requirements. EFFECT: improved method of preparing. 7 cl, 5 tbl, 5 ex
Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see Overdosage (10)]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of HYSINGLA ER, the risk is greatest during the initiation of therapy or following a dosage increase.

To reduce the risk of respiratory depression, proper dosing and titration of HYSINGLA ER are essential [see Dosage and Administration (2.1, 2.3)]. Overestimating the HYSINGLA ER dosage when converting patients from another opioid product can result in fatal overdose with the first dose.

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in respiratory depression and death due to an overdose of hydrocodone.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose.

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration (2.4)].

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose: Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with HYSINGLA ER. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered.

Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient. Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose. If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone [see Dosage and Administration (2.2), Warnings and Precautions (5.1, 5.3), Overdosage (10)].
More than 1.1 million people in the Netherlands have a mild intellectual disability (MID). They are relatively more likely to have poor oral health. The aim of this study was to investigate the oral health of MID young adults with multiple problems (such as addiction). A questionnaire was administered orally to 76 inpatient clients of the Salvation Army in Amsterdam and intraoral examinations were also performed. The research group consisted of young adults with MID and additional multi-problems. The collected data was compared with a reference group (Dutch young adults with a low socio-economic status). The results suggest that oral hygiene is poor in this population, and that a more internal locus of control is associated with a higher caries index. The findings of this study emphasize the importance of professional oral care in young adults with MID given poor oral hygiene and treatment delays. A tailor-made approach with more flexibility in treatment is essential to provide young adults with MID the right oral care.
The invention provides a PIM kinase inhibitor with a structural formula as a compound represented as a formula I. The invention also provides an isomer, a non-enantiomer, an enantiomer, a tautomer, and a salt of the compound represented by the formula I. In the formula I, E, J, Q, X, Y, Z, and m are defined as in the Claim 1. As a result of a PIM kinase biochemical activity test method, the compound (1-122) provided by the invention has a substantial inhibiting effect against PIM-1 kinase activity. Under a concentration of 3mumol, a PIM-1 kinase activity inhibiting rate exceeds 50%, and can reach a maximal value of 100%. All preferred compounds have equivalent inhibiting effect against PIM-2 and PIM-3 kinase activities. When a compound concentration is 3mumol, maximal values of PIM-2 and PIM-3 kinase activity inhibiting rates reach 100%. Therefore, the PIM kinase inhibitor provided by the invention can be applied in preparing medicines used for treating or preventing cancers, autoimmune diseases, allergic reaction diseases, or organ transplant rejection. The PIM kinase inhibitor has great clinical application values. The invention also provides a preparation method of the PIM kinase inhibitor.